95 KB20 KB192920262004Čibej, LaraHrovatin-Kralj, JanaMlakar, UrošModic, Mojcastr. I-39-I-42ISSN:1318-0347COBISSID_HOST:17679577URN:URN:NBN:SI:doc-SNVB5KLDslSlovensko zdravniško društvoZdravniški vestnikAngiogenesis FactorAngiogenetski faktorEndotelij žilniEndothelium, VascularFibroblast Growth Factor, BasicFibroblastni, rastni faktor bazičniGelatinasesMultiple MyelomaMultipli mielomŽelatinazeKoncentracije nekaterih dejavnikov angiogeneze v serumu pri diseminiranem plazmocitomu: VEGF, bFGF in MMP-9| Serum concentrations of some angiogeneic factors in multiple myeloma: VEGF, bFGF in MMP-9|Background. Angiogenesis is a crucial process in progression of multiple myeloma. Vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) are multifunctional cytokines that stimulate angiogenesisand myeloma growth. Matrix metalloproteinase 9 (MMP-9) plays a critical role in osteolytic bone destruction, angiogenesis and invasive growthof myeloma cells. We evaluated serum concentrations of these factors in patients with multiple myeloma. Methods. Levels of active and pro-matrix metalloproteinase 9 (total MMP-9), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were determined with a commercial quantitative enzyme immunoassay Quantikiner (R and D Systems, USA). All of these factors were measured in the serum, obtained from pheripheral blood of 36 patients affected by multiple myeloma. This series included 12 patients with disease in plateau phase and without treatment, 24 patients on Thalidomide therapy and 10 patients at the beginning of chemotherapy because of active disease. Results. VEGF showed a strong correlation with MMP-9 while VEGF and bFGF did not correlate with each other. Blood platelets correlated with VEGF and MMP-9. The concentration of MMP-9 and VEGF were the highest in group of patients with active disease where the chemotherapy started. The level of bFGF was the lowest in the group devoid of treatment (plateau phase of disease). Conclusions. Production of the angiogenic factors such as VEGF, bFGF and MMP-9 are increased in multiple myeloma patients. The levels of thesefactors correlate with the activity of diseaseIzhodišča. Angiogeneza ima pomembno vlogo v patogenezi in napredovanju diseminiranega plazmocitoma (DP). Žilni endotelijski rastni dejavnik A (VEGF-A) in bazični fibroblastni rastni dejavnik (bFGF, FGF2) sta citokirta, ki spodbujata angiogenezo in delitev plazmocitonaskih celic. Matriks metaloproteaza-9 je encim, ki razgrajuje zunajcelični matriks. Njegovo delovanje je pomembno pri angiogenezi, širjenju celic novotvorbe v sosednje tkivo in za osteolitično razgradnjo kosti pri plazmocitomu. V naši raziskavi smo analizirali serumske koncentracije omenjenih dejavnikov pri DP. Preiskovanci in metode. Koncentracije VEGF-A, bFGF in MMP9 smo določili pri 36bolnikih z DP. Dvanajst bolnikov z DP v obdobju, določanja dejavnikov angiogeneze ni potrebovalo zdravljenja, 14 bolnikov je prejemalo talidomid. Pri desetih bolnikih z razširjeno boleznijo smo določili angiogenetične dejavnike tik pred ali kmalu po začetku zdravljenja s citostatiki. Serumske koncentracijo MMP-9, VEGFA in bFGF smo določili na encimsko imunski način z reagenčnimi kompleti Quantikiner (R and D Systems, USA). Rezultati. Koncentraciji MMP-9 in VEGF sta bili največji v skupini bolnikov z aktivno boleznijo. Koncentracija bFGF je bila najmanjša pri bolnikih, ki niso potrebovali zdravljenja, ker je bila bolezen v obdobju remisije. Ugotovili smodobro statistično povezanost med MMP-9 in VEGF. Koncentraciji VEGF in bFGF nista bili medsebojno povezani. Število trombocitov pa je bilo povezano z VEGFin MMP-6. Zaključki. Določanje dejavnikov angiogeneze je pomembno pri oceni aktivnosti bolezni. Koncentracije teh dejavnikov so večje pri bolnikih zaktivno razširjeno boleznijoTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo